C12N 2710/16723
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2710/16723 (Virus like particles [vlp]) appears on 9 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 9
- Assignees
- 6
- Inventors
- 14
- Latest grant
- 2 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 1 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses2 Apr 2024US 11,944,677 B2Verimmune Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses29 Mar 2022US 11,285,203 B2Verimmune Inc.
- VLPS derived from cells that do not express a viral matrix or core protein5 Jul 2016US 9,381,239 B2Novavax, Inc.
- VLPs derived from cells that do not express a viral matrix or core protein15 Apr 2014US 8,697,088 B2Novavax, Inc.
- Equine herpesvirus glycoproteins8 Apr 2003US 6,544,526 B1The University of Melbourne
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses28 Nov 2024US 2024/0390473 A1Verimmune Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses21 Jul 2022US 2022/0226460 A1Verimmune Inc.
- Virus like particle production in plants28 Jan 2021US 2021/0023205 A1Medicago Inc.
- Virus like particle production in plants12 Nov 2020US 2020/0353071 A1Medicago Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses16 Apr 2020US 2020/0113996 A1Pathovax LLC
Most cited
By later US patents
- Equine herpesvirus glycoproteins13US 6,193,983 B1The University of Melbourne · 2001
- Self-assembling replication defective hybrid virus particles10US 5,420,026 ATherion Biologics Corporation · 1995
- Equine herpesvirus glycoproteins10US 6,544,526 B1The University of Melbourne · 2003
- Equine herpes virus glycoproteins8US 5,922,327 AThe University of Melbourne · 1999
- VLPs derived from cells that do not express a viral matrix or core protein8US 8,697,088 B2Novavax, Inc. · 2014